US ups fund­ing for Mod­er­na Covid-19 vac­cine as to­tal nears $6B

The US gov­ern­ment poured mon­ey in­to Mod­er­na as it sought to speed its Covid-19 vac­cine to mar­ket. In hind­sight, the in­vest­ments worked, and the US may end up in­vest­ing about $6 bil­lion in Mod­er­na’s vac­cine when all is said and done, ac­cord­ing to a com­pa­ny SEC fil­ing Wednes­day.

The lat­est funds from the Bio­med­ical Ad­vanced Re­search and De­vel­op­ment Au­thor­i­ty, up to $236 mil­lion more, will re­im­burse for Mod­er­na’s costs as­so­ci­at­ed with the vac­cine’s Phase III clin­i­cal tri­al, as well as phar­ma­covig­i­lance ef­forts to track the vac­cine’s safe­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER